Oncology Institute (TOI) Asset Writedowns and Impairment (2021 - 2023)

Oncology Institute (TOI) has reported Asset Writedowns and Impairment for 3 consecutive years, with $2.0 million the latest figure, recorded in Q4 2023.

• Asset Writedowns and Impairment for Q4 2023 came in at $2.0 million, up 2587.84% year-over-year; the trailing twelve-month figure through Sep 2024 was $2.0 million (up 1794.29% YoY), and the FY2023 annual result was $2.0 million, up 324.37% from the prior year.
• Asset Writedowns and Impairment was $2.0 million for Q4 2023 at Oncology Institute, up from $33000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $2.0 million in Q4 2023 and troughed at -$722000.0 in Q2 2021.
• Average Asset Writedowns and Impairment over 3 years is $189000.0, with a median of $74000.0 recorded in 2022.
• The widest YoY moves for Asset Writedowns and Impairment: up 2587.84% in 2023, down 102.86% in 2023.
• Over 3 years, Asset Writedowns and Impairment stood at $250000.0 in 2021, then tumbled by 70.4% to $74000.0 in 2022, then soared by 2587.84% to $2.0 million in 2023.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $2.0 million in Q4 2023, $33000.0 in Q3 2023, and -$3000.0 in Q2 2023.